U.S. markets close in 3 hours 11 minutes
  • S&P 500

    3,566.99
    +9.45 (+0.27%)
     
  • Dow 30

    29,470.54
    +207.06 (+0.71%)
     
  • Nasdaq

    11,854.35
    -0.62 (-0.01%)
     
  • Russell 2000

    1,814.43
    +29.09 (+1.63%)
     
  • Crude Oil

    42.98
    +0.56 (+1.32%)
     
  • Gold

    1,836.20
    -36.20 (-1.93%)
     
  • Silver

    23.58
    -0.78 (-3.19%)
     
  • EUR/USD

    1.1844
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    0.8490
    +0.0200 (+2.41%)
     
  • GBP/USD

    1.3315
    +0.0023 (+0.17%)
     
  • USD/JPY

    104.3200
    +0.4920 (+0.47%)
     
  • BTC-USD

    18,336.44
    -118.31 (-0.64%)
     
  • CMC Crypto 200

    362.84
    +1.41 (+0.39%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    25,527.37
    -106.93 (-0.42%)
     

What Kind Of Investors Own Most Of Atomo Diagnostics Limited (ASX:AT1)?

Simply Wall St
·5 min read

If you want to know who really controls Atomo Diagnostics Limited (ASX:AT1), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

With a market capitalization of AU$186m, Atomo Diagnostics is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about Atomo Diagnostics.

View our latest analysis for Atomo Diagnostics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Atomo Diagnostics?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Atomo Diagnostics does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Atomo Diagnostics' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Atomo Diagnostics. Dalraida Holdings Pty Limited is currently the largest shareholder, with 12% of shares outstanding. In comparison, the second and third largest shareholders hold about 11% and 7.4% of the stock. Furthermore, CEO John Kelly is the owner of 1.3% of the company's shares.

We did some more digging and found that 9 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.

Insider Ownership Of Atomo Diagnostics

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our most recent data indicates that insiders own a reasonable proportion of Atomo Diagnostics Limited. Insiders have a AU$20m stake in this AU$186m business. I would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public holds a 37% stake in Atomo Diagnostics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

Private equity firms hold a 11% stake in Atomo Diagnostics. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Private Company Ownership

We can see that Private Companies own 25%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Atomo Diagnostics better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Atomo Diagnostics , and understanding them should be part of your investment process.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.